<ul>
<li>3 只被低估的股票在本财报季有反弹潜力</li>
</ul>
<p>Scholar Rock NASDAQ: SRRK 表示，美国食品药品监督管理局已接受其重新提交的生物制品许可申请（BLA）以审查 apitegromab，这是一种针对脊髓性肌萎缩症儿童和成人的研究性治疗，并设定了 2026 年 9 月 30 日的 PDUFA 行动日期。</p>
<p>董事长兼首席执行官 David Hallal 表示，接受的申请包括两个填充和封闭设施：Catalent 在印第安纳州的工厂和第二个美国本土设施。他表示，这为公司提供了 “两个独立的 apitegromab 批准路径”。</p>
<p>此更新是在去年九月发出的完整回应信之后，Scholar Rock 表示该信件仅与对 Novo Nordisk 所拥有和运营的 Catalent 印第安纳州填充和封闭设施的例行一般现场检查的观察有关。Hallal 表示，FDA 此后已完成对该设施的未通知重新检查，并且根据 FDA 指南，机构有最多 90 天的时间来对该地点进行分类。</p>
<p>Hallal 表示，Scholar Rock 在三月底重新提交了 BLA，“与 FDA 完全一致”，以包括两个生产地点。公司表示，FDA 审查和潜在批准所需的 apitegromab 药物产品已从第二个设施提交，并预计在第三季度初可从该设施获得商业供应，提前于 9 月 30 日的行动日期。</p>
<h2>公司表示推出可能在 PDUFA 日期之前进行</h2>
<p>Scholar Rock 高管们反复表示，公司准备在获得批准后立即推出 apitegromab，包括在正式的 PDUFA 日期之前。对此，Hallal 在回答分析师提问时表示，涉及制造问题的 II 类重新提交有时可以在截止日期之前获得行动。</p>
<p>“我们只知道我们需要做好准备，因为很多时候 II 类重新提交和行动可以在该 PDUFA 日期之前由机构采取，” Hallal 说。</p>
<p>研发总裁 Akshay Vaishnaw 表示，公司预计 apitegromab 将在第三季度末之前获得针对儿童和成人 SMA 的批准，可能由一个或两个填充和封闭设施支持。</p>
<p>Vaishnaw 还讨论了欧洲的监管流程，表示公司的市场授权申请正在通过 EMA 审查。他表示，Scholar Rock 和 EMA 原定举行口头解释会议，但在双方提前达成一致后，该会议不再需要。公司仍然预计在年中接近 CHMP 意见。</p>
<p>Vaishnaw 指出，欧洲的批准还需要 FDA 对 Catalent 印第安纳州设施的批准。Hallal 表示，欧洲监管机构已被告知 FDA 过程，并在时间上 “非常灵活”。</p>
<h2>商业准备专注于 SMA 治疗中心和支付方</h2>
<p>首席运营官 Keith Woods 表示，Scholar Rock 的美国商业团队正在为 “在获得批准后立即” 推出做准备，这可能在 9 月 30 日之前的任何时间发生。他表示，肌肉力量和运动功能仍然是近十年来 SMN 目标治疗引入后未满足的主要需求，引用公司参考的数据，95% 的患者仍然经历持续和渐进的肌肉萎缩。</p>
<p>Woods 表示，Cure SMA 分享的数据表明，约三分之一的美国 SMA 患者接受了两种或更多 SMN 目标治疗，无论是顺序还是组合。他表示，公司将此视为未满足需求的证据，以及 apitegromab 作为肌肉靶向治疗的机会。</p>
<p>公司表示，其美国现场团队已接触到约 140 个 SMA 治疗中心、2600 名开处方医生和多学科护理团队。Woods 表示，Scholar Rock 正在准备其患者服务项目 Scholar Rock Supports，以为患者、护理人员和提供者提供个性化支持。</p>
<p>在问答环节中，Woods 表示，公司已扩大了护理地点规划，包括通过合作伙伴接入美国超过 10,000 名家庭输液护士。他还表示，Scholar Rock 已扩大其专科药房网络，以便患者不必为不同的 SMA 治疗使用多个专科药房。</p>
<p>在欧洲，Woods 表示，Scholar Rock 已在瑞士建立了区域总部，并在德国设立了当地领导团队，预计在 EMA 批准后推出。他表示，公司已在德国招聘了医疗和商业现场团队，并正在招募患者参与同情用药计划。</p>
<h2>管道包括 SMA 婴儿、FSHD 和皮下项目</h2>
<p>除了待处理的 SMA 申请外，Vaishnaw 表示，Scholar Rock 正在继续招募和给患者施药于 II 期 OPAL 试验，该试验评估 apitegromab 在 2 岁以下婴儿和幼儿中的效果。该研究包括接受 SMN1 目标基因治疗或正在接受 SMN2 目标治疗的参与者。</p>
<p>公司还准备启动一项随机、双盲、安慰剂对照的 II 期试验，名为 FORGE，针对面肩肱肌萎缩症（FSHD）。Vaishnaw 表示，该研究预计将很快开始招募，计划包括 60 名患者。他将 FSHD 描述为一种罕见的神经肌肉疾病，在美国和欧洲有超过 30,000 名确诊患者，且没有批准的治疗方案。</p>
<p>Vaishnaw 表示，Scholar Rock 根据未满足的需求、FLExDUX4 小鼠模型的前临床数据以及先前的随机研究表明，肌肉质量的增加可能与 FSHD 的功能益处相关，优先考虑 FSHD。</p>
<p>Scholar Rock 还在推进 apitegromab 的皮下制剂。Vaishnaw 表示，1 期数据显示，1 月份呈现出良好的生物利用度和与静脉给药相当的药效学特征。公司计划在 apitegromab 获得批准后，稍后与美国和欧洲监管机构进行接洽。</p>
<p>公司还讨论了 SRK-439，在准备好的发言中被描述为一种新型高效能抗肌肉抑制素抗体，目前处于第一阶段。Vaishnaw 表示，健康志愿者研究中的给药正在进行中，预计今年晚些时候会有初步数据。</p>
<h2>第一季度现金状况增强</h2>
<p>首席财务官 Vikas Sinha 表示，Scholar Rock 在 2026 年第一季度结束时拥有 4.8 亿美元的现金及现金等价物和可交易证券。总额包括公司在 3 月份从现有债务融资中提取的 1 亿美元和本季度通过市场股权计划获得的 9800 万美元净现金收益。</p>
<p>Sinha 表示，第一季度的运营费用为 1.02 亿美元，扣除基于股票的补偿后，运营费用为 8400 万美元。他表示，Scholar Rock 在 2026 年的财务优先事项仍然集中在支持商业发布准备、资助研发项目以及评估加强资产负债表的机会。</p>
<p>在 FDA 批准 apitegromab 后，Sinha 表示 Scholar Rock 将有机会从现有债务融资中提取额外的 1.5 亿美元。公司还计划变现优先审查凭证，以进一步增强其资产负债表。</p>
<p>Hallal 在电话会议结束时表示，Scholar Rock 专注于为生活在脊髓性肌萎缩症（SMA）中的儿童和成人提供其所描述的首个肌肉靶向疗法，同时建立更广泛的神经肌肉疾病管线。</p>
<h2>关于 Scholar Rock NASDAQ: SRRK</h2>
<p>Scholar Rock 是一家临床阶段的生物技术公司，专注于发现和开发选择性靶向参与疾病过程的生长因子的蛋白质治疗。公司的研究平台旨在以高特异性调节内源性生长因子的激活和信号传导，旨在恢复一系列疾病的正常生物功能。Scholar Rock 的方法以其强调工程化抗体和生物制剂与生长因子前体或潜在复合物的相互作用而非活性形式而有所区别，可能提供更好的安全性和有效性。</p>
<p>公司的主导项目 SRK-015（appercept）是一种针对潜在肌肉抑制素前蛋白激活的研究性单克隆抗体，正在评估用于治疗脊髓性肌萎缩症（SMA）。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Scholar Rock 更好</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Scholar Rock 吗？</h2>
<p>在你考虑投资 Scholar Rock 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Scholar Rock 并不在名单上。</p>
<p>虽然 Scholar Rock 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SRRK

IBBQ

标普生物技术 ETF - SPDR

<p>Scholar Rock（纳斯达克股票代码：SRRK）宣布，FDA 已接受其重新提交的生物制品许可申请（Biologics License Application），该申请针对治疗脊髓性肌萎缩症的药物 apitegromab，PDUFA 行动日期定于 2026 年 9 月 30 日。首席执行官 David Hallal 指出，申请中包括了两个制造地点以供批准。该公司正在为在获得批准后立即推出 apitegromab 做准备，商业准备工作正在进行中。此外，Scholar Rock 正在推进其欧洲监管流程，并在美国扩展其患者服务项目，以支持 SMA 治疗中心和患者</p>

<ul>
<li>3 Beaten-Down Stocks With Rebound Potential This Earnings Season</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的股票在本财报季有反弹潜力</li>
</ul>
</div><p>Scholar Rock NASDAQ: SRRK said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026.</p>
<div class="lb-trans"><p>Scholar Rock NASDAQ: SRRK 表示，美国食品药品监督管理局已接受其重新提交的生物制品许可申请（BLA）以审查 apitegromab，这是一种针对脊髓性肌萎缩症儿童和成人的研究性治疗，并设定了 2026 年 9 月 30 日的 PDUFA 行动日期。</p>
</div><p>Chairman and Chief Executive Officer David Hallal said the accepted filing includes two fill-finish facilities: Catalent’s Indiana site and a second U.S.-based facility. He said that gives the company “two independent paths to apitegromab approval.”</p>
<div class="lb-trans"><p>董事长兼首席执行官 David Hallal 表示，接受的申请包括两个填充和封闭设施：Catalent 在印第安纳州的工厂和第二个美国本土设施。他表示，这为公司提供了 “两个独立的 apitegromab 批准路径”。</p>
</div><p>The update follows a complete response letter issued last September, which Scholar Rock said was tied solely to observations from a routine general site inspection of the Catalent, Indiana fill-finish facility, owned and operated by Novo Nordisk. Hallal said the FDA has since completed an unannounced re-inspection of that facility, and that under FDA guidelines, the agency has up to 90 days to classify the site.</p>
<div class="lb-trans"><p>此更新是在去年九月发出的完整回应信之后，Scholar Rock 表示该信件仅与对 Novo Nordisk 所拥有和运营的 Catalent 印第安纳州填充和封闭设施的例行一般现场检查的观察有关。Hallal 表示，FDA 此后已完成对该设施的未通知重新检查，并且根据 FDA 指南，机构有最多 90 天的时间来对该地点进行分类。</p>
</div><p>Hallal said Scholar Rock resubmitted the BLA in late March “in complete alignment with the FDA” to include both manufacturing sites. The company said the apitegromab drug product required for FDA review and potential approval from the second facility has been filed, and it expects to have commercial supply from that facility available in early third quarter, ahead of the Sept. 30 action date.</p>
<div class="lb-trans"><p>Hallal 表示，Scholar Rock 在三月底重新提交了 BLA，“与 FDA 完全一致”，以包括两个生产地点。公司表示，FDA 审查和潜在批准所需的 apitegromab 药物产品已从第二个设施提交，并预计在第三季度初可从该设施获得商业供应，提前于 9 月 30 日的行动日期。</p>
</div><h2>Company Says Launch Could Come Before PDUFA Date</h2>
<div class="lb-trans"><h2>公司表示推出可能在 PDUFA 日期之前进行</h2>
</div><p>Scholar Rock executives repeatedly said the company is preparing to launch apitegromab immediately if approved, including ahead of the formal PDUFA date. In response to an analyst question, Hallal said Class II resubmissions related to manufacturing issues can sometimes receive action before the deadline.</p>
<div class="lb-trans"><p>Scholar Rock 高管们反复表示，公司准备在获得批准后立即推出 apitegromab，包括在正式的 PDUFA 日期之前。对此，Hallal 在回答分析师提问时表示，涉及制造问题的 II 类重新提交有时可以在截止日期之前获得行动。</p>
</div><p>“We just know that we need to be prepared because many times Class 2 resubmissions and action can be taken by the agency well ahead of that PDUFA date,” Hallal said.</p>
<div class="lb-trans"><p>“我们只知道我们需要做好准备，因为很多时候 II 类重新提交和行动可以在该 PDUFA 日期之前由机构采取，” Hallal 说。</p>
</div><p>Akshay Vaishnaw, president of R&amp;D, said the company anticipates approval of apitegromab for children and adults with SMA “by the end of the Q3,” potentially supported by either or both fill-finish facilities.</p>
<div class="lb-trans"><p>研发总裁 Akshay Vaishnaw 表示，公司预计 apitegromab 将在第三季度末之前获得针对儿童和成人 SMA 的批准，可能由一个或两个填充和封闭设施支持。</p>
</div><p>Vaishnaw also discussed the European regulatory process, saying the company’s Marketing Authorization Application is progressing through EMA review. He said Scholar Rock and the EMA had been scheduled for an oral explanation meeting, but the meeting was no longer needed after the two sides aligned in advance. The company continues to expect a CHMP opinion near mid-year.</p>
<div class="lb-trans"><p>Vaishnaw 还讨论了欧洲的监管流程，表示公司的市场授权申请正在通过 EMA 审查。他表示，Scholar Rock 和 EMA 原定举行口头解释会议，但在双方提前达成一致后，该会议不再需要。公司仍然预计在年中接近 CHMP 意见。</p>
</div><p>Vaishnaw noted that approval in Europe also requires FDA clearance of the Catalent Indiana facility. Hallal said European regulators have been kept informed about the FDA process and have been “very flexible” on timing.</p>
<div class="lb-trans"><p>Vaishnaw 指出，欧洲的批准还需要 FDA 对 Catalent 印第安纳州设施的批准。Hallal 表示，欧洲监管机构已被告知 FDA 过程，并在时间上 “非常灵活”。</p>
</div><h2>Commercial Preparation Focuses on SMA Treatment Centers and Payers</h2>
<div class="lb-trans"><h2>商业准备专注于 SMA 治疗中心和支付方</h2>
</div><p>Chief Operating Officer Keith Woods said Scholar Rock’s U.S. commercial team is preparing for launch “immediately upon approval,” which could occur any time through Sept. 30. He said muscle strength and motor function remain major unmet needs nearly a decade after the introduction of SMN-targeted therapies, citing company-referenced data that 95% of patients continue to experience persistent and progressive muscle atrophy.</p>
<div class="lb-trans"><p>首席运营官 Keith Woods 表示，Scholar Rock 的美国商业团队正在为 “在获得批准后立即” 推出做准备，这可能在 9 月 30 日之前的任何时间发生。他表示，肌肉力量和运动功能仍然是近十年来 SMN 目标治疗引入后未满足的主要需求，引用公司参考的数据，95% 的患者仍然经历持续和渐进的肌肉萎缩。</p>
</div><p>Woods said data shared by Cure SMA indicated that about one-third of people living with SMA in the U.S. have received two or more SMN-targeted treatments, either sequentially or in combination. He said the company views that as evidence of remaining unmet need and an opportunity for apitegromab as a muscle-targeted therapy.</p>
<div class="lb-trans"><p>Woods 表示，Cure SMA 分享的数据表明，约三分之一的美国 SMA 患者接受了两种或更多 SMN 目标治疗，无论是顺序还是组合。他表示，公司将此视为未满足需求的证据，以及 apitegromab 作为肌肉靶向治疗的机会。</p>
</div><p>The company said its U.S. field team has reached approximately 140 SMA treatment centers, 2,600 prescribing physicians and multidisciplinary care teams. Woods said Scholar Rock is preparing its patient services program, Scholar Rock Supports, to provide individualized support to patients, caregivers and providers.</p>
<div class="lb-trans"><p>公司表示，其美国现场团队已接触到约 140 个 SMA 治疗中心、2600 名开处方医生和多学科护理团队。Woods 表示，Scholar Rock 正在准备其患者服务项目 Scholar Rock Supports，以为患者、护理人员和提供者提供个性化支持。</p>
</div><p>During the question-and-answer session, Woods said the company has expanded site-of-care planning, including access through partners to more than 10,000 home infusion nurses across the U.S. He also said Scholar Rock has expanded its specialty pharmacy network so patients do not have to use multiple specialty pharmacies for different SMA treatments.</p>
<div class="lb-trans"><p>在问答环节中，Woods 表示，公司已扩大了护理地点规划，包括通过合作伙伴接入美国超过 10,000 名家庭输液护士。他还表示，Scholar Rock 已扩大其专科药房网络，以便患者不必为不同的 SMA 治疗使用多个专科药房。</p>
</div><p>In Europe, Woods said Scholar Rock has established its regional headquarters in Switzerland and has local leadership in place in Germany, where it expects to launch following EMA approval. He said the company has hired medical and commercial field teams in Germany and is enrolling patients in a compassionate use program.</p>
<div class="lb-trans"><p>在欧洲，Woods 表示，Scholar Rock 已在瑞士建立了区域总部，并在德国设立了当地领导团队，预计在 EMA 批准后推出。他表示，公司已在德国招聘了医疗和商业现场团队，并正在招募患者参与同情用药计划。</p>
</div><h2>Pipeline Includes SMA Infants, FSHD and Subcutaneous Programs</h2>
<div class="lb-trans"><h2>管道包括 SMA 婴儿、FSHD 和皮下项目</h2>
</div><p>Beyond the pending SMA application, Vaishnaw said Scholar Rock is continuing to enroll and dose patients in the Phase 2 OPAL trial, which is evaluating apitegromab in infants and toddlers under age 2. The study includes participants treated with SMN1-targeted gene therapy or receiving ongoing SMN2-targeted therapy.</p>
<div class="lb-trans"><p>除了待处理的 SMA 申请外，Vaishnaw 表示，Scholar Rock 正在继续招募和给患者施药于 II 期 OPAL 试验，该试验评估 apitegromab 在 2 岁以下婴儿和幼儿中的效果。该研究包括接受 SMN1 目标基因治疗或正在接受 SMN2 目标治疗的参与者。</p>
</div><p>The company is also preparing to initiate a randomized, double-blind, placebo-controlled Phase 2 trial called FORGE in facioscapulohumeral muscular dystrophy, or FSHD. Vaishnaw said the study is expected to begin enrollment soon and will include 60 patients. He described FSHD as a rare neuromuscular disease with more than 30,000 diagnosed patients in the U.S. and Europe and no approved therapies.</p>
<div class="lb-trans"><p>公司还准备启动一项随机、双盲、安慰剂对照的 II 期试验，名为 FORGE，针对面肩肱肌萎缩症（FSHD）。Vaishnaw 表示，该研究预计将很快开始招募，计划包括 60 名患者。他将 FSHD 描述为一种罕见的神经肌肉疾病，在美国和欧洲有超过 30,000 名确诊患者，且没有批准的治疗方案。</p>
</div><p>Vaishnaw said Scholar Rock prioritized FSHD based on unmet need, preclinical data from the FLExDUX4 mouse model and prior randomized studies suggesting that increases in muscle mass may be associated with functional benefit in FSHD.</p>
<div class="lb-trans"><p>Vaishnaw 表示，Scholar Rock 根据未满足的需求、FLExDUX4 小鼠模型的前临床数据以及先前的随机研究表明，肌肉质量的增加可能与 FSHD 的功能益处相关，优先考虑 FSHD。</p>
</div><p>Scholar Rock is also advancing a subcutaneous formulation of apitegromab. Vaishnaw said Phase 1 data presented in January showed favorable bioavailability and a pharmacodynamic profile comparable to intravenous administration. The company plans to engage U.S. and European regulators later this year following apitegromab approval.</p>
<div class="lb-trans"><p>Scholar Rock 还在推进 apitegromab 的皮下制剂。Vaishnaw 表示，1 期数据显示，1 月份呈现出良好的生物利用度和与静脉给药相当的药效学特征。公司计划在 apitegromab 获得批准后，稍后与美国和欧洲监管机构进行接洽。</p>
</div><p>The company also discussed SRK-439, described in prepared remarks as a novel high-potency anti-myostatin antibody currently in Phase 1. Vaishnaw said dosing in a healthy volunteer study is progressing and that top-line data are expected later this year.</p>
<div class="lb-trans"><p>公司还讨论了 SRK-439，在准备好的发言中被描述为一种新型高效能抗肌肉抑制素抗体，目前处于第一阶段。Vaishnaw 表示，健康志愿者研究中的给药正在进行中，预计今年晚些时候会有初步数据。</p>
</div><h2>Cash Position Strengthened in First Quarter</h2>
<div class="lb-trans"><h2>第一季度现金状况增强</h2>
</div><p>Chief Financial Officer Vikas Sinha said Scholar Rock ended the first quarter of 2026 with $480 million in cash equivalents and marketable securities. The total includes a $100 million drawdown from the company’s existing debt facility in March and $98 million in net cash proceeds from its at-the-market equity program during the quarter.</p>
<div class="lb-trans"><p>首席财务官 Vikas Sinha 表示，Scholar Rock 在 2026 年第一季度结束时拥有 4.8 亿美元的现金及现金等价物和可交易证券。总额包括公司在 3 月份从现有债务融资中提取的 1 亿美元和本季度通过市场股权计划获得的 9800 万美元净现金收益。</p>
</div><p>Sinha said first-quarter operating expenses were $102 million, and that operating expenses excluding stock-based compensation were $84 million. He said Scholar Rock’s 2026 financial priorities remain focused on supporting commercial launch readiness, funding R&amp;D programs and evaluating opportunities to strengthen the balance sheet.</p>
<div class="lb-trans"><p>Sinha 表示，第一季度的运营费用为 1.02 亿美元，扣除基于股票的补偿后，运营费用为 8400 万美元。他表示，Scholar Rock 在 2026 年的财务优先事项仍然集中在支持商业发布准备、资助研发项目以及评估加强资产负债表的机会。</p>
</div><p>Upon FDA approval of apitegromab, Sinha said Scholar Rock will have the option to draw an additional $150 million from its existing debt facility. The company also plans to monetize a priority review voucher to further strengthen its balance sheet.</p>
<div class="lb-trans"><p>在 FDA 批准 apitegromab 后，Sinha 表示 Scholar Rock 将有机会从现有债务融资中提取额外的 1.5 亿美元。公司还计划变现优先审查凭证，以进一步增强其资产负债表。</p>
</div><p>Hallal closed the call by saying Scholar Rock is focused on bringing what it describes as the first muscle-targeted therapy to children and adults living with SMA while building a broader neuromuscular disease pipeline.</p>
<div class="lb-trans"><p>Hallal 在电话会议结束时表示，Scholar Rock 专注于为生活在脊髓性肌萎缩症（SMA）中的儿童和成人提供其所描述的首个肌肉靶向疗法，同时建立更广泛的神经肌肉疾病管线。</p>
</div><h2>About Scholar Rock NASDAQ: SRRK</h2>
<div class="lb-trans"><h2>关于 Scholar Rock NASDAQ: SRRK</h2>
</div><p>Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.</p>
<div class="lb-trans"><p>Scholar Rock 是一家临床阶段的生物技术公司，专注于发现和开发选择性靶向参与疾病过程的生长因子的蛋白质治疗。公司的研究平台旨在以高特异性调节内源性生长因子的激活和信号传导，旨在恢复一系列疾病的正常生物功能。Scholar Rock 的方法以其强调工程化抗体和生物制剂与生长因子前体或潜在复合物的相互作用而非活性形式而有所区别，可能提供更好的安全性和有效性。</p>
</div><p>The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).</p>
<div class="lb-trans"><p>公司的主导项目 SRK-015（appercept）是一种针对潜在肌肉抑制素前蛋白激活的研究性单克隆抗体，正在评估用于治疗脊髓性肌萎缩症（SMA）。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Scholar Rock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Scholar Rock 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Scholar Rock Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Scholar Rock 吗？</h2>
</div><p>Before you consider Scholar Rock, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Scholar Rock 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Scholar Rock 并不在名单上。</p>
</div><p>While Scholar Rock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Scholar Rock 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Scholar Rock 第一季度财报电话会议亮点